Dermata Therapeutics Inc (NASDAQ:DRMA) — Market Cap & Net Worth
Market Cap & Net Worth: Dermata Therapeutics Inc (DRMA)
Dermata Therapeutics Inc (NASDAQ:DRMA) has a market capitalization of $4.67 Million ($4.67 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28809 globally and #5899 in its home market, demonstrating a -4.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dermata Therapeutics Inc's stock price $1.16 by its total outstanding shares 4022143 (4.02 Million). Also see total assets of Dermata Therapeutics Inc for a full breakdown of the balance sheet.
Dermata Therapeutics Inc Market Cap History: 2021 to 2026
Dermata Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.68 Billion to $4.67 Million (-74.56% CAGR). Also see DRMA cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Dermata Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #832 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2672 of 3165 |
Weight: Dermata Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dermata Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dermata Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Dermata Therapeutics Inc (DRMA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DRMA by Market Capitalization
Companies near Dermata Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Dermata Therapeutics Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dermata Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Dermata Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Dermata Therapeutics Inc's market cap moved from $1.68 Billion to $ 4.67 Million, with a yearly change of -74.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.67 Million | -50.00% |
| 2025 | $9.33 Million | +71.85% |
| 2024 | $5.43 Million | -85.25% |
| 2023 | $36.80 Million | -90.68% |
| 2022 | $394.81 Million | -76.49% |
| 2021 | $1.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Dermata Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.67 Million USD |
| MoneyControl | $4.67 Million USD |
| MarketWatch | $4.67 Million USD |
| marketcap.company | $4.67 Million USD |
| Reuters | $4.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more